ataluren
Selected indexed studies
- Ataluren-Promising Therapeutic Premature Termination Codon Readthrough Frontrunner. (Pharmaceuticals (Basel), 2021) [PMID:34451881]
- Ataluren: first global approval. (Drugs, 2014) [PMID:25193627]
- ** (, 2023) [PMID:40258099]
_Worker-drafted node — pending editorial review._
Connections
ataluren is a side effect of
Sources
- Ataluren-Promising Therapeutic Premature Termination Codon Readthrough Frontrunner. (2021) pubmed
- Ataluren: first global approval. (2014) pubmed
- PMID:40258099 (2023) pubmed
- Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis. (2023) pubmed
- Ataluren improves hematopoietic and pancreatic disorders in Shwachman-Diamond syndrome patients: a compassionate program case-series. (2025) pubmed
- Effect of Ataluren on dystrophin mutations. (2020) pubmed
- Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. (2020) pubmed
- Ataluren suppresses a premature termination codon in an MPS I-H mouse. (2022) pubmed
- Ataluren in cystic fibrosis: development, clinical studies and where are we now? (2017) pubmed
- Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients. (2022) pubmed